|
|
Article: Northfield's PolyHeme Passes Third Phase III Interim Analysis.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Northfield Laboratories Inc.'s stock jumped 31.6 percent Monday after an independent data monitoring committee gave the go-ahead for the ongoing Phase III trial of PolyHeme.
It is the first time a hemoglobin-based oxygen therapeutic has surpassed the third planned interim analysis milestone without requests for modification to a trial in high-risk trauma patients. The committee's decision was based on blinded mortality data in the first 250 people enrolled.
"This is a validation of everything to date and we are very gratified to have reached this point," said Steven Gould, chairman and CEO of Evanston, Ill.-based Northfield.
...